CR Extras: Supplementary Materials for Counselling Resource Readers

CR Extras

Medication Reference Materials

Research and Clinical Trials on Gabapentin (Neurontin, Gabarone)

By CounsellingResource Research Staff |

This list of current clinical research trials on Gabapentin (Neurontin, Gabarone) is followed by a short set of abstracts from the most recent research articles published on the drug.

Article Contents

Gabapentin (Neurontin, Gabarone) Clinical Research Trials

From our searchable database at ClinicalTrialsFeeds.org, this list includes all the latest information about clinical trials involving Gabapentin (Neurontin, Gabarone).

 

Get These Clinical Trials as a Newsfeed

Gabapentin:     Get the Fluvoxamine clinical trials feed.    Add the Fluvoxamine clinical trials feed to your My Yahoo! page.    Add the Fluvoxamine clinical trials feed to your MyMSN page.

Current Research Literature on Gabapentin (Neurontin, Gabarone)

Here are abstracts for some of the latest research articles to have appeared on Gabapentin (Neurontin, Gabarone):

Multiple sclerosis.

Clin Evid (Online). 2012; 2012:
Nicholas R, Rashid W
Multiple sclerosis is the most common cause of neurological disability in young adults. Irreversible disability can occur, but life expectancy is generally not affected. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions aimed at reducing relapse rates and disability in people with multiple sclerosis? What are the effects of interventions to improve symptoms during acute relapse? What are the effects of treatments for fatigue, spasticity, and multidisciplinary care on disability in people with multiple sclerosis? We searched: Medline, Embase, The Cochrane Library, and other important databases up to July 2011 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).We found 71 systematic reviews, RCTs, and observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.In this systematic review, we present information relating to the effectiveness and safety of the following key interventions: amantadine, azathioprine, behaviour modification, botulinum toxin, corticosteroids, exercise, gabapentin, inpatient or outpatient rehabilitation, interferon beta, intrathecal baclofen, intravenous immunoglobulin, methotrexate, mitoxantrone, modafinil, natalizumab, oral drug treatments, parenteral glatiramer acetate, physiotherapy, and plasma exchange.

Assessment of prescribers' knowledge of the cost of medications.

Ann Pharmacother. 2012 Feb; 46(2): 200-7
Cogdill B, Nappi JM
In 2003, the World Health Organization reported that 50% of patients are adherent to long-term therapies. Frequently, the reason for a patient's nonadherence is the cost of medications. Even with prescription insurance coverage, patients may not be able to afford their medications.To assess prescriber knowledge of the cost of commonly prescribed medications including atorvastatin, gabapentin, levofloxacin, losartan, pantoprazole, pioglitazone, and quetiapine. SecondaryOne hundred prescribers from the Medical University of South Carolina were surveyed from November 2010 to January 2011. Prescribers consisted of medical residents, attending physicians, fellows, nurse practitioners, and physician assistants. Wholesale prices of medications were determined using the Red Book, and prescription insurance prices were calculated from an average of the top 3 prescription insurance companies' copayments.Medical residents made up 72% of those surveyed, fellows 3%, attending physicians 12%, physician assistants 3%, and nurse practitioners 10%. The prescriber groups were unable to correctly determine the cost of medications of more than 50% of total possible responses. The majority of prescribers rarely asked about a patient's prescription insurance coverage or consulted a discounted drug list before writing a prescription.Prescribers are more likely to know the cost of medications for patients who have prescription insurance coverage versus those who do not.

Sleep in patients with epilepsy.

Acta Neurol Taiwan. 2011 Dec; 20(4): 229-131
Kwan SY
Sleep disorder is common in all societies, so are in the patients with epilepsy (PWE). In the International Classification of Sleep Disorders (ICSD) published 2001, it is categorized into four main subsidiaries, which are (1) dyssomnias, (2) parasomnias, (3) sleep disorders associated with mental, neurologic, or other medical disorders and (4) proposed sleep disorders (1). No matter what the final diagnosis is, the results usually are poor quality of sleep and excessive daytime sleepiness. There are complex pathophysiologic mechanisms that underlie the interaction of sleep and epilepsy. These include (1) epilepsy seizure per se, (2) psychotic and psychiatric impact from epilepsy and (3) side effects from antiepileptic drugs (AEDs). In PWE, poor sleep quality causes sleep deprivation, which in turn exaggerates the attacks of seizures and falls into vicious cycles. Thus, it is worth paying attention to this field. Sleep is an extremely valuable physiological activating technique in epilepsy and is used routinely in the electroencephalographic (EEG) recording. The importance in the activation of epileptiform discharges (EDs) during sleep was first demonstrated by Gibbs and Gibbs in 1947 (2). It is proposed that non-rapid eye movement (NREM) sleep and rapid eye movement (REM) sleep have contrasting effects on ictal and interictal EDs. EDs are likely to propagate during NREM sleep, including its synchronized EEG transients, such as K-complexes and sleep spindles. In contrast, REM sleep, with its asynchronous cellular discharge patterns and skeletal motor paralysis, is resistant to propagation of EDs and to clinical motor accompaniment. In addition, the preserved skeletal muscle tone in NREM permits seizure-related movement, whereas the lower motor neuron inhibition in REM prevents seizure-related movement (3). These can explain why clinical seizures and interictal EDs tend to occur in NREM rather than REM sleep. Seizures markedly activated by sleep including the seizures of frontal lobe origin and the generalized tonic seizures of Lenox-Gastaut syndrome. The epilepsies that having interictal EDs markedly activated during NREM sleep include benign rolandic epilepsy, temporal lobe epilepsy and infantile spasm. While the Landau-Kleffner syndrome and the atypical benign rolandic epilepsy possess the most striking increase of EDs with continuous spike-and-wave complexes during slow wave sleep (CSWS) or electrical status epilepticus during sleep (ESES) in EEG (Figure 1) and absence of normal sleep activities. On days after nocturnal seizures, patients had more severe excessive daytime sleepiness as compared with days after seizure free nights. As compared with seizurefree nights, nights with seizures were characterized by a reduction of REM and stage 3 sleep, prolonged REM latency and reduced sleep efficiency(4). These findings held true even on seizure-free nights. Nocturnal generalized seizures would decrease sleep time and REM sleep percentage, prolong REM latency, and fragment sleep(5). Multiple focal seizures in a night also significantly reduced REM sleep. In addition, not only seizures occurring at night but also those occurring during the day can affect sleep architecture, with proved significant reduction of REM sleep and prolongation REM latency in the following nights(6). Psychological or psychiatric problems, having a high incidence in PWE, may also play a role in disturbing normal sleep. It was reported that 40% of respondents with insomnia and 46.5% of respondents with hypersomnia had a psychiatric disorder. Anxiety disorders were found to be the most common mental disorders (7). Another study found that 93% of depressed inpatients complained of insomnia (8). In PWE, depression is the most frequent comorbid psychiatric disorder, with a prevalence of 10% to 20% among patients with controlled seizures and 20% to 60% among those with refractory epilepsy(9,10). The prevalence of anxiety disorder, panic disorder, obsessive-compulsive disorder and phobias is also high in PWE, with estimates of 3% to 66% (10). Psychosis consisting of visual or auditory illusions and hallucinations, paranoia, depersonalization, derealization, autoscopy, or delusion is reported in 0.6% to 7% of PWE in the community, and in 19% to 27% of hospital-derived populations (11). The overall frequency of psychosis among PWE is approximately 7% to 14%. Reports suggest that up to 69% of patients with temporal lobe epilepsy and 72% of patients with generalized epilepsy suffer from personality disorders (12). Even as benign as juvenile myoclonic epilepsy, 14% was reported to have personality disorders (13). Sleep disturbance in PWE may be secondary to AEDs they are treated with. Most old AEDs were reported to result in a normalization of the sleep architecture and sleep efficiency (14). Studies suggest that phenytoin (PHT), phenobarbital (PB), carbmazepine (CBZ) and clonazepam (CZP) can decrease sleep latency. PB and ethosuximide (ESM) can decrease awakening and arousal. CBZ and CZP can decrease wake time after sleep onset. PHT, PB and ESM can increased stage 1 and stage 2 sleep. CZP can increase stage 2 sleep. PHT, CBZ and valproic acid (VPA) can increased slow wave sleep. PB, VPA and CZP can decrease REM sleep. In newer AEDs, gabapentin (GBP) can decrease awakening and arousal but increased slow wave sleep (14). However, AEDs can also have negative effect on sleep architecture. VPA and ESM can increase awakening and arousal. VPA can increase wake time after sleep onset. PHT, CZP and ESM can decrease slow wave sleep. ESM will increase REM sleep. In newer AEDs, GBP can increase REM sleep, lamotrigine produced somnolence in 14% and insomnia in 6% of patients. Topiramate produced somnolence in approximately 30% of patients treated. Somnolence and insomnia occurred in 18 and 6%, respectively of patients receiving tiagabine(15). The mechanisms of sleep disorders related to AEDs are complex, some related to their direct sedative effect on central nervous system, and can be ameliorated by gradual escalating the dosages when initiation of treatment. Some are more complicated, for example, the slow wave sleep-enhancing effects were thought to reflect the effect of CBZ on 5-hydroxytryptamine (5-HT) levels or its effect on adenosine receptors that modulate the release of 5-HT and catecholamines (16). Therefore, it is not difficult to expect that sleep disorders are more prevalent in patients with polytherapy than in those with monotherapy and improved after reducing the number of AEDs. Under the invention of modern diagnostic tools especially video monitoring with polysomnography, the types and causes of sleep disorders are much easier to be clarified than before. In the paper "Sleep Quality and Daytime Sleepiness in Patients with Epilepsy" by Chen NC et al (Acta Neurologica Taiwanica Vol 21 No 2 June 2011), they adopted self-rated questionales of Epworth Sleepiness Scale (ESS) and the Pittsburg Sleep Quality Index (PSQI) as tools to estimate excessive daytime sleepiness and sleep quality. They had three main findings: (1) Twenty percent of PWE (23/117) in contrast to 7% of healthy controls (2/30) had excessive daytime sleepiness. (2) There is a significantly higher prevalence of poor sleep quality in the partial seizure, non-seizurefree, and polytherapy groups. (3) The poor seizure control was the strongest independent risk factor for poor sleep quality. Their findings are consistent with the studies in the past decades and worth paying appreciation for it has been the first large scale study in Taiwanese PWE (117 cases) ever since. Indeed, the complex relationship between epilepsy and sleep disorder must be addressed in order to provide the best management of sleep disturbance in PWE.

Efficacy of Gabapentin for Prevention of Postoperative Catheter-related Bladder Discomfort in Patients Undergoing Transurethral Resection of Bladder Tumor.

Urology. 2012 Feb 4;
Bala I, Bharti N, Chaubey VK, Mandal AK
OBJECTIVE: To evaluate the effect of 600 mg and 1200 mg oral gabapentin pretreatment for the prevention of postoperative catheter-related bladder discomfort (CRBD) in patients undergoing catheterization after transurethral resection of bladder tumor (TURBT). MATERIALS AND METHODS: One hundred adult patients undergoing elective TURBT under spinal anesthesia were randomly allocated into 3 groups. Group I patients received placebo, group II patients received 600 mg gabapentin, and group III patients received 1200 mg gabapentin 1 hour before surgery. Lumber subarachnoid block was administered with 2.5 mL 0.5% hyperbaric bupivacaine. The patients were observed for the incidence and severity of CRBD in the postoperative period. RESULTS: The incidence of CRBD was 90% in group I, 66% in group II, and 26% in group III. The incidence of bladder discomfort was significantly low in group III at all time points compared with group I and at 4, 6, 12, and 24 hours compared with group II. The severity of CRBD was also less in group II and III patients compared with group I. Fifteen patients in group I developed moderate discomfort, whereas 1 patient in group II and none in group III. None of the patient receiving gabapentin had severe discomfort. The duration and level of sensory and motor block was comparable among groups. One patient in group II and 2 patients in group III were complained of dizziness in postoperative period. CONCLUSION: Gabapentin 1200 mg administered before surgery is more effective than gabapentin 600 mg in decreasing the incidence of postoperative CRBD.

Analgesic effects of preoperative gabapentin after tongue reconstruction with the anterolateral thigh flap.

Hong Kong Med J. 2012 Feb; 18(1): 30-4
Chiu TW, Leung CCh, Lau EY, Burd A
OBJECTIVE. To investigate gabapentin's role in head and neck cancer surgery following the demonstration of the effectiveness of gabapentin in reducing postoperative pain. DESIGN. Non-randomised open-label trial. SETTING. Prince of Wales Hospital, Hong Kong. MAIN OUTCOME MEASURES. Pain scores, analgesic usage, and the frequency of adverse effects. PATIENTS. In patients undergoing anterolateral thigh flap reconstruction after resection of tongue carcinoma, those who had an oral dose of gabapentin before surgery were compared to those who did not. RESULTS. Postoperative pain was reduced in the gabapentin group (1.2) compared to the control group (1.7) [P=0.05]. In the gabapentin group, mean morphine (patient-controlled analgesia) use (3.5 mg), sedation scores (1.0), and antiemetic usage (0 mg metoclopramide) were all significantly reduced in comparison to the controls with respective figures of 11.4 mg, 1.6, and 12.2 mg. CONCLUSION. Single preoperative doses of gabapentin led to significant reductions in postoperative pain and nausea with reduced analgesic and antiemetic usage, without additional side-effects or increases in operative complications.